Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06131385
Recruiting Observational

Registration of Intravenous Thrombolysis for Acute Ischemic Stroke in Southwestern China（IVTIS）

NCT06131385 · tracked via the Priya Life Science China tracker
Sponsor
Zhengzhou Yuan
Phase
Observational
Started
2023-11-20
Last updated
2023-11-28

Condition(s) studied

Stroke, Acute

Investigational drug(s) / intervention(s)

intravenous thrombolysis

intravenous thrombolysis: Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.

Study summary

This study aims to observe the safety and effectiveness of intravenous thrombolysis for acute ischemic stroke in real-world clinical practice.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * The patient was diagnosed with acute ischemic stroke and received intravenous thrombolysis. Exclusion Criteria: * No additional exclusion criteria.

Primary outcome measure(s)

  • modified Rankin Scale (mRS) score — 90±7 days
    Ordinal distribution of mRS at 90±7 days; modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)

Trial sites (1)

FacilityCityRegionStatus
Affiliated Hospital of Southwest Medical University Luzhou China Recruiting

More Zhengzhou Yuan trials in China

Registration of Acute Ischemic Stroke With Large and Medium-sized Vascular Occlusion in Southwest China(LMVOS) Recruiting

Other trials for the same condition

The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy Recruiting
Prospective Cohort of Patients With Intracerebral Hemorrhage Recruiting
HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) Recruiting
Therapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion Recruiting
A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06131385 on ClinicalTrials.gov ↗ ← All trials in China